KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Pacira BioSciences (PCRX) Net Margin (2016 - 2025)

Pacira BioSciences (PCRX) has 16 years of Net Margin data on record, last reported at 0.83% in Q4 2025.

  • For Q4 2025, Net Margin fell 773.0% year-over-year to 0.83%; the TTM value through Dec 2025 reached 0.97%, up 1517.0%, while the annual FY2025 figure was 0.97%, 1517.0% up from the prior year.
  • Net Margin reached 0.83% in Q4 2025 per PCRX's latest filing, down from 3.03% in the prior quarter.
  • Across five years, Net Margin topped out at 15.2% in Q2 2023 and bottomed at 85.11% in Q3 2024.
  • Average Net Margin over 5 years is 0.49%, with a median of 4.85% recorded in 2022.
  • Peak YoY movement for Net Margin: plummeted -9695bps in 2021, then surged 8813bps in 2025.
  • A 5-year view of Net Margin shows it stood at 3.22% in 2021, then crashed by -85bps to 5.97% in 2022, then soared by 330bps to 13.72% in 2023, then crashed by -38bps to 8.57% in 2024, then tumbled by -90bps to 0.83% in 2025.
  • Per Business Quant database, its latest 3 readings for Net Margin were 0.83% in Q4 2025, 3.03% in Q3 2025, and 2.68% in Q2 2025.